Cargando…

Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study

Objectives To quantify the diagnostic accuracy of selected inflammatory markers in addition to symptoms and signs for predicting pneumonia and to derive a diagnostic tool. Design Diagnostic study performed between 2007 and 2010. Participants had their history taken, underwent physical examination an...

Descripción completa

Detalles Bibliográficos
Autores principales: van Vugt, Saskia F, Broekhuizen, Berna D L, Lammens, Christine, Zuithoff, Nicolaas P A, de Jong, Pim A, Coenen, Samuel, Ieven, Margareta, Butler, Chris C, Goossens, Herman, Little, Paul, Verheij, Theo J M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639712/
https://www.ncbi.nlm.nih.gov/pubmed/23633005
http://dx.doi.org/10.1136/bmj.f2450
_version_ 1782475984937680896
author van Vugt, Saskia F
Broekhuizen, Berna D L
Lammens, Christine
Zuithoff, Nicolaas P A
de Jong, Pim A
Coenen, Samuel
Ieven, Margareta
Butler, Chris C
Goossens, Herman
Little, Paul
Verheij, Theo J M
author_facet van Vugt, Saskia F
Broekhuizen, Berna D L
Lammens, Christine
Zuithoff, Nicolaas P A
de Jong, Pim A
Coenen, Samuel
Ieven, Margareta
Butler, Chris C
Goossens, Herman
Little, Paul
Verheij, Theo J M
author_sort van Vugt, Saskia F
collection PubMed
description Objectives To quantify the diagnostic accuracy of selected inflammatory markers in addition to symptoms and signs for predicting pneumonia and to derive a diagnostic tool. Design Diagnostic study performed between 2007 and 2010. Participants had their history taken, underwent physical examination and measurement of C reactive protein (CRP) and procalcitonin in venous blood on the day they first consulted, and underwent chest radiography within seven days. Setting Primary care centres in 12 European countries. Participants Adults presenting with acute cough. Main outcome measures Pneumonia as determined by radiologists, who were blind to all other information when they judged chest radiographs. Results Of 3106 eligible patients, 286 were excluded because of missing or inadequate chest radiographs, leaving 2820 patients (mean age 50, 40% men) of whom 140 (5%) had pneumonia. Re-assessment of a subset of 1675 chest radiographs showed agreement in 94% (κ 0.45, 95% confidence interval 0.36 to 0.54). Six published “symptoms and signs models” varied in their discrimination (area under receiver operating characteristics curve (ROC) ranged from 0.55 (95% confidence interval 0.50 to 0.61) to 0.71 (0.66 to 0.76)). The optimal combination of clinical prediction items derived from our patients included absence of runny nose and presence of breathlessness, crackles and diminished breath sounds on auscultation, tachycardia, and fever, with an ROC area of 0.70 (0.65 to 0.75). Addition of CRP at the optimal cut off of >30 mg/L increased the ROC area to 0.77 (0.73 to 0.81) and improved the diagnostic classification (net reclassification improvement 28%). In the 1556 patients classified according to symptoms, signs, and CRP >30 mg/L as “low risk” (<2.5%) for pneumonia, the prevalence of pneumonia was 2%. In the 132 patients classified as “high risk” (>20%), the prevalence of pneumonia was 31%. The positive likelihood ratio of low, intermediate, and high risk for pneumonia was 0.4, 1.2, and 8.6 respectively. Measurement of procalcitonin added no relevant additional diagnostic information. A simplified diagnostic score based on symptoms, signs, and CRP >30 mg/L resulted in proportions of pneumonia of 0.7%, 3.8%, and 18.2% in the low, intermediate, and high risk group respectively. Conclusions A clinical rule based on symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough performed best in patients with mild or severe clinical presentation. Addition of CRP concentration at the optimal cut off of >30 mg/L improved diagnostic information, but measurement of procalcitonin concentration did not add clinically relevant information in this group.
format Online
Article
Text
id pubmed-3639712
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-36397122013-04-30 Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study van Vugt, Saskia F Broekhuizen, Berna D L Lammens, Christine Zuithoff, Nicolaas P A de Jong, Pim A Coenen, Samuel Ieven, Margareta Butler, Chris C Goossens, Herman Little, Paul Verheij, Theo J M BMJ Research Objectives To quantify the diagnostic accuracy of selected inflammatory markers in addition to symptoms and signs for predicting pneumonia and to derive a diagnostic tool. Design Diagnostic study performed between 2007 and 2010. Participants had their history taken, underwent physical examination and measurement of C reactive protein (CRP) and procalcitonin in venous blood on the day they first consulted, and underwent chest radiography within seven days. Setting Primary care centres in 12 European countries. Participants Adults presenting with acute cough. Main outcome measures Pneumonia as determined by radiologists, who were blind to all other information when they judged chest radiographs. Results Of 3106 eligible patients, 286 were excluded because of missing or inadequate chest radiographs, leaving 2820 patients (mean age 50, 40% men) of whom 140 (5%) had pneumonia. Re-assessment of a subset of 1675 chest radiographs showed agreement in 94% (κ 0.45, 95% confidence interval 0.36 to 0.54). Six published “symptoms and signs models” varied in their discrimination (area under receiver operating characteristics curve (ROC) ranged from 0.55 (95% confidence interval 0.50 to 0.61) to 0.71 (0.66 to 0.76)). The optimal combination of clinical prediction items derived from our patients included absence of runny nose and presence of breathlessness, crackles and diminished breath sounds on auscultation, tachycardia, and fever, with an ROC area of 0.70 (0.65 to 0.75). Addition of CRP at the optimal cut off of >30 mg/L increased the ROC area to 0.77 (0.73 to 0.81) and improved the diagnostic classification (net reclassification improvement 28%). In the 1556 patients classified according to symptoms, signs, and CRP >30 mg/L as “low risk” (<2.5%) for pneumonia, the prevalence of pneumonia was 2%. In the 132 patients classified as “high risk” (>20%), the prevalence of pneumonia was 31%. The positive likelihood ratio of low, intermediate, and high risk for pneumonia was 0.4, 1.2, and 8.6 respectively. Measurement of procalcitonin added no relevant additional diagnostic information. A simplified diagnostic score based on symptoms, signs, and CRP >30 mg/L resulted in proportions of pneumonia of 0.7%, 3.8%, and 18.2% in the low, intermediate, and high risk group respectively. Conclusions A clinical rule based on symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough performed best in patients with mild or severe clinical presentation. Addition of CRP concentration at the optimal cut off of >30 mg/L improved diagnostic information, but measurement of procalcitonin concentration did not add clinically relevant information in this group. BMJ Publishing Group Ltd. 2013-04-30 /pmc/articles/PMC3639712/ /pubmed/23633005 http://dx.doi.org/10.1136/bmj.f2450 Text en © van Vugt et al 2013 http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.
spellingShingle Research
van Vugt, Saskia F
Broekhuizen, Berna D L
Lammens, Christine
Zuithoff, Nicolaas P A
de Jong, Pim A
Coenen, Samuel
Ieven, Margareta
Butler, Chris C
Goossens, Herman
Little, Paul
Verheij, Theo J M
Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study
title Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study
title_full Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study
title_fullStr Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study
title_full_unstemmed Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study
title_short Use of serum C reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study
title_sort use of serum c reactive protein and procalcitonin concentrations in addition to symptoms and signs to predict pneumonia in patients presenting to primary care with acute cough: diagnostic study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639712/
https://www.ncbi.nlm.nih.gov/pubmed/23633005
http://dx.doi.org/10.1136/bmj.f2450
work_keys_str_mv AT vanvugtsaskiaf useofserumcreactiveproteinandprocalcitoninconcentrationsinadditiontosymptomsandsignstopredictpneumoniainpatientspresentingtoprimarycarewithacutecoughdiagnosticstudy
AT broekhuizenbernadl useofserumcreactiveproteinandprocalcitoninconcentrationsinadditiontosymptomsandsignstopredictpneumoniainpatientspresentingtoprimarycarewithacutecoughdiagnosticstudy
AT lammenschristine useofserumcreactiveproteinandprocalcitoninconcentrationsinadditiontosymptomsandsignstopredictpneumoniainpatientspresentingtoprimarycarewithacutecoughdiagnosticstudy
AT zuithoffnicolaaspa useofserumcreactiveproteinandprocalcitoninconcentrationsinadditiontosymptomsandsignstopredictpneumoniainpatientspresentingtoprimarycarewithacutecoughdiagnosticstudy
AT dejongpima useofserumcreactiveproteinandprocalcitoninconcentrationsinadditiontosymptomsandsignstopredictpneumoniainpatientspresentingtoprimarycarewithacutecoughdiagnosticstudy
AT coenensamuel useofserumcreactiveproteinandprocalcitoninconcentrationsinadditiontosymptomsandsignstopredictpneumoniainpatientspresentingtoprimarycarewithacutecoughdiagnosticstudy
AT ievenmargareta useofserumcreactiveproteinandprocalcitoninconcentrationsinadditiontosymptomsandsignstopredictpneumoniainpatientspresentingtoprimarycarewithacutecoughdiagnosticstudy
AT butlerchrisc useofserumcreactiveproteinandprocalcitoninconcentrationsinadditiontosymptomsandsignstopredictpneumoniainpatientspresentingtoprimarycarewithacutecoughdiagnosticstudy
AT goossensherman useofserumcreactiveproteinandprocalcitoninconcentrationsinadditiontosymptomsandsignstopredictpneumoniainpatientspresentingtoprimarycarewithacutecoughdiagnosticstudy
AT littlepaul useofserumcreactiveproteinandprocalcitoninconcentrationsinadditiontosymptomsandsignstopredictpneumoniainpatientspresentingtoprimarycarewithacutecoughdiagnosticstudy
AT verheijtheojm useofserumcreactiveproteinandprocalcitoninconcentrationsinadditiontosymptomsandsignstopredictpneumoniainpatientspresentingtoprimarycarewithacutecoughdiagnosticstudy